{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T19:14:02Z","timestamp":1783710842565,"version":"3.55.0"},"reference-count":72,"publisher":"Xia & He Publishing","issue":"000","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,28]]},"DOI":"10.14218\/jcth.2020.00078","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T02:26:51Z","timestamp":1610936811000},"page":"000-000","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and Safety of Glecaprevir\/Pibrentasvir in Patients with Chronic HCV Infection"],"prefix":"10.14218","volume":"000","author":[{"given":"Xiaoqing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5334","published-online":{"date-parts":[[2021,1,18]]},"reference":[{"key":"key20210118022643_JCTH-D-20-00078-b1","unstructured":"World Health Organization. Global hepatitis report, 2017. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255016\/9789241565455-eng.pdf"},{"key":"key20210118022643_JCTH-D-20-00078-b2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.gastro.2018.10.033","article-title":"What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection?","volume":"156","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"key20210118022643_JCTH-D-20-00078-b3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.13673","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int"},{"key":"key20210118022643_JCTH-D-20-00078-b4","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"key20210118022643_JCTH-D-20-00078-b5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"key20210118022643_JCTH-D-20-00078-b6","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jhep.2017.11.032","article-title":"Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir\/velpatasvir in the phase III studies","volume":"68","author":"Hezode","year":"2018","journal-title":"J Hepatol"},{"key":"key20210118022643_JCTH-D-20-00078-b7","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/liv.14535","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with HCV genotype 5\/6: An integrated analysis of phase 2\/3 studies","volume":"40","author":"Yao","year":"2020","journal-title":"Liver Int"},{"key":"key20210118022643_JCTH-D-20-00078-b8","unstructured":"MAVYRET\u00ae(glecaprevir and pibrentasvir), US prescribing information. Available from: https:\/\/www.rxabbvie.com\/pdf\/mavyret_pi.pdf"},{"key":"key20210118022643_JCTH-D-20-00078-b9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist Updat"},{"key":"key20210118022643_JCTH-D-20-00078-b10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jcph.1524","article-title":"Population pharmacokinetics of glecaprevir\/pibrentasvir in HCV-infected Japanese subjects in phase 3 CERTAIN-1 and CERTAIN-2 trials","volume":"60","author":"Suleiman","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"key20210118022643_JCTH-D-20-00078-b11","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/jcph.959","article-title":"Pharmacokinetics, safety, and tolerability of glecaprevir and pibrentasvir in healthy white, Chinese, and Japanese adult subjects","volume":"57","author":"Lin","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"key20210118022643_JCTH-D-20-00078-b12","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/2050640616678151","article-title":"The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions","volume":"5","author":"Smolders","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"key20210118022643_JCTH-D-20-00078-b13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00535-017-1391-5","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis","volume":"53","author":"Chayama","year":"2018","journal-title":"J Gastroenterol"},{"key":"key20210118022643_JCTH-D-20-00078-b14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hep.29510","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection","volume":"67","author":"Toyoda","year":"2018","journal-title":"Hepatology"},{"key":"key20210118022643_JCTH-D-20-00078-b15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2468-1253(18)30341-8","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial","volume":"4","author":"Asselah","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"key20210118022643_JCTH-D-20-00078-b16","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/apt.15222","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry","volume":"49","author":"Berg","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"key20210118022643_JCTH-D-20-00078-b17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8 weeks in treatment-na\u00efve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial","volume":"72","author":"Brown","year":"2020","journal-title":"J Hepatol"},{"key":"key20210118022643_JCTH-D-20-00078-b18","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key20210118022643_JCTH-D-20-00078-b19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J Hepatol"},{"key":"key20210118022643_JCTH-D-20-00078-b20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.29541","article-title":"Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: A partially randomized phase 3 clinical trial","volume":"67","author":"Wyles","year":"2018","journal-title":"Hepatology"},{"key":"key20210118022643_JCTH-D-20-00078-b21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/liv.14386","article-title":"Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort","volume":"40","author":"Soria","year":"2020","journal-title":"Liver Int"},{"key":"key20210118022643_JCTH-D-20-00078-b22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12072-020-10019-z","article-title":"The effectiveness and safety of glecaprevir\/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study","volume":"14","author":"Nozaki","year":"2020","journal-title":"Hepatol Int"},{"key":"key20210118022643_JCTH-D-20-00078-b23","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/hepr.13410","article-title":"Intention-to-treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world","volume":"49","author":"Tamori","year":"2019","journal-title":"Hepatol Res"},{"key":"key20210118022643_JCTH-D-20-00078-b24","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/jgh.14874","article-title":"Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection","volume":"35","author":"Toyoda","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"key20210118022643_JCTH-D-20-00078-b25","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"key":"key20210118022643_JCTH-D-20-00078-b26","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/liv.14320","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic HCV infection","volume":"40","author":"Lawitz","year":"2020","journal-title":"Liver Int"},{"key":"key20210118022643_JCTH-D-20-00078-b27","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/apt.15218","article-title":"The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study","volume":"49","author":"Atsukawa","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"key20210118022643_JCTH-D-20-00078-b28","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jvh.13265","article-title":"Glecaprevir\/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment","volume":"27","author":"Liu","year":"2020","journal-title":"J Viral Hepat"},{"key":"key20210118022643_JCTH-D-20-00078-b29","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/cid\/ciy220","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: The EXPEDITION-2 study","volume":"67","author":"Rockstroh","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key20210118022643_JCTH-D-20-00078-b30","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.30046","article-title":"Glecaprevir\/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection","volume":"68","author":"Reau","year":"2018","journal-title":"Hepatology"},{"key":"key20210118022643_JCTH-D-20-00078-b31","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00535-019-01561-1","article-title":"Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience","volume":"54","author":"Ueda","year":"2019","journal-title":"J Gastroenterol"},{"key":"key20210118022643_JCTH-D-20-00078-b32","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.29671","article-title":"Glecaprevir\/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure","volume":"67","author":"Poordad","year":"2018","journal-title":"Hepatology"},{"key":"key20210118022643_JCTH-D-20-00078-b33","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00535-018-01543-9","article-title":"NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir","volume":"54","author":"Uemura","year":"2019","journal-title":"J Gastroenterol"},{"key":"key20210118022643_JCTH-D-20-00078-b34","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.30840","article-title":"Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in adolescents with chronic hepatitis C virus: Part 1 of the DORA study","volume":"71","author":"Jonas","year":"2020","journal-title":"Hepatology"},{"key":"key20210118022643_JCTH-D-20-00078-b35","first-page":"379","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol","volume":"70","author":"D\u2019Ambrosio","year":"2019"},{"key":"key20210118022643_JCTH-D-20-00078-b36","first-page":"1187","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir in Asian patients with chronic hepatitis C. J Formos Med Assoc","volume":"118","author":"Hsu","year":"2019"},{"key":"key20210118022643_JCTH-D-20-00078-b37","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/jvh.13170","article-title":"Evaluation of 8-week glecaprevir\/pibrentasvir treatment in direct-acting antiviral-na\u00efve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan","volume":"26","author":"Ikeda","year":"2019","journal-title":"J Viral Hepat"},{"key":"key20210118022643_JCTH-D-20-00078-b38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20210118022643_JCTH-D-20-00078-b39","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"key20210118022643_JCTH-D-20-00078-b40","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00535-018-1520-9","article-title":"Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures","volume":"54","author":"Osawa","year":"2019","journal-title":"J Gastroenterol"},{"key":"key20210118022643_JCTH-D-20-00078-b41","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1007\/s12325-019-01123-0","article-title":"Efficacy and safety of 8 weeks of glecaprevir\/pibrentasvir in treatment-na\u00efve, HCV-infected patients with APRI\u2009\u2264\u20091 in a single-arm, open-label, multicenter study","volume":"36","author":"Fontana","year":"2019","journal-title":"Adv Ther"},{"key":"key20210118022643_JCTH-D-20-00078-b42","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1053\/j.gastro.2019.08.008","article-title":"Efficacy of glecaprevir and pibrentasvir in patients with genotype 1 hepatitis C virus infection with treatment failure after NS5A inhibitor plus sofosbuvir therapy","volume":"157","author":"Lok","year":"2019","journal-title":"Gastroenterology"},{"key":"key20210118022643_JCTH-D-20-00078-b43","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/liv.14170","article-title":"Real-life glecaprevir\/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study","volume":"39","author":"Persico","year":"2019","journal-title":"Liver Int"},{"key":"key20210118022643_JCTH-D-20-00078-b44","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/liv.14295","article-title":"Glecaprevir\/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan","volume":"40","author":"Liu","year":"2020","journal-title":"Liver Int"},{"key":"key20210118022643_JCTH-D-20-00078-b45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3390\/biomedicines8040074","article-title":"Effectiveness of glecaprevir\/pibrentasvir for hepatitis C: Real-world experience and clinical features of retreatment cases","volume":"8","author":"Sugiura","year":"2020","journal-title":"Biomedicines"},{"key":"key20210118022643_JCTH-D-20-00078-b46","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/hepr.13387","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ribavirin regimen","volume":"49","author":"Kusakabe","year":"2019","journal-title":"Hepatol Res"},{"key":"key20210118022643_JCTH-D-20-00078-b47","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00535-019-01575-9","article-title":"Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1\/2\/3 infections","volume":"54","author":"Sezaki","year":"2019","journal-title":"J Gastroenterol"},{"key":"key20210118022643_JCTH-D-20-00078-b48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","article-title":"High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis","volume":"69","author":"Puoti","year":"2018","journal-title":"J Hepatol"},{"key":"key20210118022643_JCTH-D-20-00078-b49","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis","volume":"72","author":"Lampertico","year":"2020","journal-title":"J Hepatol"},{"key":"key20210118022643_JCTH-D-20-00078-b50","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jvh.13038","article-title":"Glecaprevir\/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2\/3 analysis","volume":"26","author":"Flamm","year":"2019","journal-title":"J Viral Hepat"},{"key":"key20210118022643_JCTH-D-20-00078-b51","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/hepr.13482","article-title":"Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study","volume":"50","author":"Morishita","year":"2020","journal-title":"Hepatol Res"},{"key":"key20210118022643_JCTH-D-20-00078-b52","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/jvh.13110","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis","volume":"26","author":"Back","year":"2019","journal-title":"J Viral Hepat"},{"key":"key20210118022643_JCTH-D-20-00078-b53","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.29081","article-title":"Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment","volume":"66","author":"Poordad","year":"2017","journal-title":"Hepatology"},{"key":"key20210118022643_JCTH-D-20-00078-b54","doi-asserted-by":"crossref","first-page":"e02217","DOI":"10.1128\/AAC.01249-18","article-title":"Integrated resistance analysis of CERTAIN-1 and CERTAIN-2 studies in hepatitis C virus-infected patients receiving glecaprevir and pibrentasvir in Japan","volume":"62","author":"Krishnan","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"key20210118022643_JCTH-D-20-00078-b55","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"key":"key20210118022643_JCTH-D-20-00078-b56","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.drugalcdep.2018.11.007","article-title":"Glecaprevir\/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies","volume":"194","author":"Foster","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"key20210118022643_JCTH-D-20-00078-b57","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugpo.2019.01.011","article-title":"Safety and efficacy of glecaprevir\/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy","volume":"66","author":"Grebely","year":"2019","journal-title":"Int J Drug Policy"},{"key":"key20210118022643_JCTH-D-20-00078-b58","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cgh.2018.07.003","article-title":"Efficacy and pharmacokinetics of glecaprevir and pibrentasvir with concurrent use of acid-reducing agents in patients with chronic HCV infection","volume":"17","author":"Flamm","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20210118022643_JCTH-D-20-00078-b59","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/cid\/ciz025","article-title":"Safety of hepatitis C viral protease inhibitors in compensated cirrhotics: Lingering concerns put to rest?","volume":"69","author":"Kiser","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key20210118022643_JCTH-D-20-00078-b60","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/cid\/ciz022","article-title":"Safety and pharmacokinetics of glecaprevir\/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infections and compensated liver disease","volume":"69","author":"Gane","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key20210118022643_JCTH-D-20-00078-b61","doi-asserted-by":"crossref","first-page":"e0208506","DOI":"10.1371\/journal.pone.0208506","article-title":"Safety and efficacy of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older","volume":"14","author":"Foster","year":"2019","journal-title":"PLoS One"},{"key":"key20210118022643_JCTH-D-20-00078-b62","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/liv.14266","article-title":"Adherence to pan-genotypic glecaprevir\/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials","volume":"40","author":"Brown","year":"2020","journal-title":"Liver Int"},{"key":"key20210118022643_JCTH-D-20-00078-b63","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/apt.15633","article-title":"Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir\/pibrentasvir among chronic hepatitis C patients","volume":"51","author":"Singh","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"key20210118022643_JCTH-D-20-00078-b64","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/hep.29837","article-title":"Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors","volume":"69","author":"Smith","year":"2019","journal-title":"Hepatology"},{"key":"key20210118022643_JCTH-D-20-00078-b65","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.antiviral.2018.08.001","article-title":"HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China","volume":"158","author":"Wei","year":"2018","journal-title":"Antiviral Res"},{"key":"key20210118022643_JCTH-D-20-00078-b66","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1038\/emi.2017.77","article-title":"Hepatitis C virus genotypes and subtypes circulating in Mainland China","volume":"6","author":"Chen","year":"2017","journal-title":"Emerg Microbes Infect"},{"key":"key20210118022643_JCTH-D-20-00078-b67","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jhep.2017.03.014","article-title":"Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses","volume":"67","author":"Welzel","year":"2017","journal-title":"J Hepatol"},{"key":"key20210118022643_JCTH-D-20-00078-b68","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.3748\/wjg.v24.i38.4304","article-title":"Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus","volume":"24","author":"Sato","year":"2018","journal-title":"World J Gastroenterol"},{"key":"key20210118022643_JCTH-D-20-00078-b69","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-0039-3402001","article-title":"NS5A-P32 deletion in hepatitis C genotype 1b infection is the most refractory treatment-mediated amino acid change exhibiting resistance to all NS5A inhibitors","volume":"40","author":"Hikita","year":"2020","journal-title":"Semin Liver Dis"},{"key":"key20210118022643_JCTH-D-20-00078-b70","first-page":"319","article-title":"Changing demographics among populations prescribed HCV treatment, 2013-2017","volume":"25","author":"Tsai","year":"2019","journal-title":"Am J Manag Care"},{"key":"key20210118022643_JCTH-D-20-00078-b71","doi-asserted-by":"crossref","first-page":"S289","DOI":"10.1016\/S0168-8278(18)30798-0","article-title":"Significant changes of HCV patient characteristics over time in the era of direct antiviral agent therapy \u2013 are all HCV subpopulations treated similarly? \u2013 Results from the German hepatitis C Cohort","volume":"68","author":"Christensen","year":"2018","journal-title":"J Hepatol"},{"key":"key20210118022643_JCTH-D-20-00078-b72","unstructured":"European Commission Grants AbbVie Marketing Authorization Shortening MAVIRET\u00ae (glecaprevir\/pibrentasvir) treatment duration to eight weeks for treatment-na\u00efve chronic HCV patients with genotype 3 and compensated cirrhosis. Available from: https:\/\/news.abbvie.com\/news\/press-releases\/european-commission-grants-abbvie-marketing-authorization-shortening-maviret-glecaprevirpibrentasvir-treatment-duration-to-eight-weeks-for-treatment-nave-chronic-hcv-patients-with-genotype-3-and-compensated-cirrhosis.htm?view_id=4284"}],"container-title":["Journal of Clinical and Translational Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2020-00078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:19:36Z","timestamp":1783707576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2020-00078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,18]]},"references-count":72,"journal-issue":{"issue":"000","published-online":{"date-parts":[[2021,1,18]]},"published-print":{"date-parts":[[2021,3,28]]}},"alternative-id":["10.14218\/JCTH.2020.00078"],"URL":"https:\/\/doi.org\/10.14218\/jcth.2020.00078","relation":{},"ISSN":["2225-0719","2310-8819"],"issn-type":[{"value":"2225-0719","type":"print"},{"value":"2310-8819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,18]]}}}